Providence St. Joseph Health Pioneers Diabetic Care in Southern California with EyeArt AI Technology
January 18, 2021 – Providence St. Joseph Health, a leading healthcare organization in southern California, recently adopted the EyeArt autonomous artificial intelligence (AI) system in 3 Southern California primary care clinics as part of an…
January 14, 2021 – Eyenuk today announced its partnership with Alta Tecnología Médica S.A. (ATM), a leading provider of advanced medical technologies in Chile for the distribution of EyeArt® artificial intelligence (AI) system for autonomous…
January 13, 2021 – The Eyenuk team has been encouraged to witness the worldwide interest and inquires related to the research paper, “Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening…
United States Department of Veterans Affairs Publishes Research with Head-to-Head AI Performance Comparison Results for Diabetic Retinopathy Detection
January 6, 2021 – The Diabetes Care Journal just published a landmark study with patient data from the United States Department of Veterans Affairs (VA). In this multicenter, noninterventional study on more than 300,000 retinal images…
December 7, 2020 – Eyenuk is pleased to announce that its EyeArt® AI System for autonomous diabetic retinopathy detection has been granted regulatory approval by INVIMA, the Colombian governmental regulatory agency that oversees healthcare. Colombia…
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.